Didanosine
- Generic Name
- Didanosine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N4O3
- CAS Number
- 69655-05-6
- Unique Ingredient Identifier
- K3GDH6OH08
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.
- Indication
For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 300
- Registration Number
- NCT00001087
- Locations
- 🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002274
- Locations
- 🇺🇸
Bristol - Myers Squibb Co, Princeton, New Jersey, United States
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00002168
- Locations
- 🇺🇸
Univ of Nebraska, Omaha, Nebraska, United States
🇺🇸Anderson Clinical Research, Washington, District of Columbia, United States
🇵🇷Hosp Regional de Ponce - Area Vieja, Ponce, Puerto Rico
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-08-16
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002028
- Locations
- 🇺🇸
Bristol - Myers Squibb Co, Princeton, New Jersey, United States
A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-26
- Target Recruit Count
- 25
- Registration Number
- NCT00000669
- Locations
- 🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸The Regional Medical Ctr, Memphis, Memphis, Tennessee, United States
🇺🇸Univ TX Health Science Ctr, Houston, Texas, United States
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00002420
- Locations
- 🇺🇸
Pacific Oaks Med Group, Beverly Hills, California, United States
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00002418
- Locations
- 🇺🇸
Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸Brown Univ School of Medicine, Providence, Rhode Island, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-04
- Target Recruit Count
- 96
- Registration Number
- NCT00000760
- Locations
- 🇺🇸
UCSD, San Diego, California, United States
🇺🇸Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Harvard (Massachusetts Gen Hosp), Boston, Massachusetts, United States
The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-04
- Lead Sponsor
- Abbott
- Target Recruit Count
- 24
- Registration Number
- NCT00000971
- Locations
- 🇺🇸
Children's Hosp of Los Angeles, Los Angeles, California, United States
🇺🇸Natl Cancer Institute / HIV / AIDS Malignancy Branch, Bethesda, Maryland, United States
A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 654
- Registration Number
- NCT00001029
- Locations
- 🇺🇸
Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.